North America Dengue Treatment Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2021 –2028 |
 Taille du marché (année de référence) |
USD 71.42 Million |
 Taille du marché (année de prévision) |
USD 387.13 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché du traitement de la dengue en Amérique du Nord, par souches (DENV-1, DENV-2, DENV-3, DENV-4, autres), transmission (transmission du moustique à l'homme et transmission de la mère à l'enfant), type (médicaments, soins de soutien, vaccination et autres), gravité (non compliquée et grave), voie d'administration (orale et parentérale), mode d'achat (sur ordonnance et en vente libre (OTC)), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (pharmacies hospitalières, pharmacies de détail, pharmacies en ligne et autres), pays (États-Unis, Canada et Mexique) Tendances et prévisions de l'industrie jusqu'en 2028
Analyse et perspectives du marché : marché nord-américain du traitement de la dengue
Le marché du traitement de la dengue devrait connaître une croissance exponentielle au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché connaît une croissance de 23,9 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 387,13 millions USD d'ici 2028, contre 71,42 millions USD. Les initiatives stratégiques des acteurs du marché et l'avènement des programmes de vaccination de masse pour le traitement de la dengue devraient être les principaux moteurs du marché du traitement de la dengue.
La dengue est une maladie virale transmise par les moustiques qui s'est rapidement propagée dans toutes les régions de l'OMS (Organisation mondiale de la santé) ces dernières années. Le virus de la dengue est principalement transmis par les moustiques femelles du genre Aedes Aegyptus et, dans une moindre mesure, par Ae. albopictus. Les maladies transmises par ces moustiques vecteurs sont le chikungunya, la fièvre jaune et le virus Zika. La dengue est répandue dans les régions tropicales, induite par les précipitations, la température , l'humidité relative et l'urbanisation rapide et non planifiée, avec une variabilité locale des risques.
Malgré les mesures contrôlées, l'augmentation mondiale de l'incidence de la dengue, ainsi que la fréquence accrue des épidémies localisées et le potentiel de prolifération des espèces d'Aedes entraînent une augmentation de la consommation de l'option thérapeutique pour le traitement de la dengue et devraient agir comme un moteur pour le marché du traitement de la dengue. Le coût du traitement de la dengue est plus élevé comme indiqué dans la déclaration ci-dessus et avec plus de complications liées à la dengue telles que la défaillance multi-organique et d'autres peuvent augmenter le coût total du traitement, ce qui conduit la personne infectée à éviter les thérapies appropriées pour le traitement de la dengue, ce qui peut agir comme un frein pour le marché du traitement de la dengue. La dengue peut être diagnostiquée traditionnellement par des tests sérologiques, mais maintenant, avec la mise à niveau technologique, différentes méthodes en cours et développées existent pour la détection du virus, ce qui créera une opportunité pour le marché du traitement de la dengue. La dengue est une maladie à transmission vectorielle avec des médicaments non spécifiques tels que les antipyrétiques et certains antibiotiques, mais les mesures préventives et les initiatives prises par les différentes agences gouvernementales dans le monde devraient constituer un défi pour le marché du traitement de la dengue.
Le rapport sur le marché du traitement de la dengue fournit des détails sur la part de marché, les nouveaux développements et l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché du traitement de la dengue en Amérique du Nord
Le marché du traitement de la dengue est segmenté en fonction des souches, de la transmission, du type, de la gravité, de la voie d'administration, du mode d'achat, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base des souches, le marché du traitement de la dengue est segmenté en DENV-1, DENV-2, DENV-3, DENV-4, etc. En 2021, le segment DENV-2 domine le marché car cette souche a une prévalence élevée, ce qui entraîne un nombre plus élevé de cas d'infection par la dengue. Bien que la dengue puisse également être causée par d'autres souches, la complication clinique la plus fréquente est observée dans le DENV-2.
- Sur la base de la transmission, le marché du traitement de la dengue est segmenté en transmission du moustique à l'homme et transmission de la mère à l'enfant. En 2021, le segment de la transmission du moustique à l'homme domine le marché car les moustiques sont le principal vecteur de transmission de la dengue pour les différentes souches du virus. Lorsqu'un moustique pique une personne infectée, il est également infecté et le virus se retrouve dans le sang, et lorsqu'il pique à nouveau une autre personne, le virus lui est transmis. C'est la raison pour laquelle la transmission du moustique à l'homme domine le marché.
- Sur la base du type, le marché du traitement de la dengue est segmenté en médicaments , soins de soutien , vaccination et autres. En 2021, le segment des médicaments domine le marché, car une variété de médicaments utilisés pour traiter la dengue sont utilisés pour la gestion de la fièvre dengue depuis très longtemps.
- En fonction de la gravité, le marché du traitement de la dengue est segmenté en deux catégories : simple et sévère. En 2021, le segment simple domine le marché : le taux de conversion de la dengue simple en dengue sévère est inférieur à 5 %, ce qui est la principale raison pour laquelle le segment simple domine le marché du traitement de la dengue.
- En fonction de la voie d'administration, le marché du traitement de la dengue est segmenté en voie orale et parentérale . En 2021, le segment oral domine le marché, car la plupart des médicaments utilisés pour traiter les symptômes de la dengue sont pris par voie orale pour la gestion de la douleur et de la fièvre.
- On the basis of mode of purchase, the dengue treatment market is segmented into prescription and over the counter (OTC). In 2021, prescription segment is dominating in the market as the medication and the supportive care is prescribed by the doctor after the confirmation the patient is infected by the dengue virus and the treatment options consist of antibiotics and other medication which are generally not available as prescribed medication only.
- On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
- On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the market as after proper diagnosis of dengue most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.
Dengue Treatment Market Country Level Analysis
The dengue treatment market is analysed and market size information is provided by the country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel as referenced above.
The countries covered in the dengue treatment market report are the U.S., Canada and Mexico.
The U.S. is expected to dominate in the North America dengue treatment market due to growing focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Necessity of Dengue Treatment in Urban Areas and the Strategic Intiatives by Market Players are is Creating New Opportunities for Players in the Dengue Treatment Market
The dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2010 to 2019.
Analyse du paysage concurrentiel et des parts de marché du traitement de la dengue
Le paysage concurrentiel du marché du traitement de la dengue fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et la portée du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché du traitement de la dengue.
Les principales sociétés proposant des traitements contre la dengue sont Aurobindo Pharma, Perrigo Company plc, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Fresenius Kabi USA (une filiale de Fresenius SE & Co. KGaA), Baxter, Vitric Inc., Hikma Pharmaceuticals PLC, Teva Pharmaceuticals USA, Inc. (une filiale de Teva Pharmaceutical Industries Ltd.), GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Sanofi et EMERGEX VACCINES, entre autres. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.
La collaboration, les coentreprises et d’autres stratégies des acteurs du marché améliorent le marché des entreprises sur le marché du traitement de la dengue, ce qui offre également l’avantage aux organisations d’améliorer leur offre pour le marché du traitement de la dengue.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA DENGUE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STRAINS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 PIPELINE ANALYSIS
6 NORTH AMERICA DENGUE TREATMENT MARKET: REGULATIONS
6.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
6.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
6.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
6.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
6.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
7 CLINICAL STUDIES FOR DENGUE TREATMENT PRODUCTS.
7.1 SYNTHETIC DRUGS
7.2 BIOMARKER
7.3 DIRECT ACTING ANTIVIRAL DRUGS
8 EPIDEMIOLOGY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING INCIDENCE IN DENGUE CASES
9.1.2 ADVENT OF VACCINATION PROGRAMS
9.1.3 INCREASE IN RESEARCH AND DEVELOPMENT FUNDING
9.1.4 ROLE OF IGM AND IGG ANTIBODIES IN DENGUE
9.1.5 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
9.2 RESTRAINTS
9.2.1 HIGH COST OF TREATMENT
9.2.2 DEARTH AWARENESS ABOUT THE SYMPTOMS OF DENGUE
9.2.3 LACK OR INSUFFICIENT HEALTHCARE INFRASTRUCTURE
9.3 OPPORTUNITIES
9.3.1 NEED FOR DENGUE TREATMENT IN URBAN AREAS
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 TECHNOLOGICAL ADVANCEMENT IN DENGUE VIRUS DETECTION
9.3.4 INCREASE IN NORTH AMERICA TRAVEL AND RELATION WITH DENGUE
9.4 CHALLENGES
9.4.1 PRESENCE OF PREVENTIVE MEASURES FOR DENGUE AND IT’S SPREAD
9.4.2 CHALLENGES IN DETECTION ASSAY FOR DENGUE
9.4.3 ALTERNATIVES FOR DENGUE TREATMENT
10 IMPACT OF COVID-19 ON NORTH AMERICA DENGUE TREATMENT MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISION BY MANUFACTURERS
10.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
10.6 CONCLUSION
11 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS
11.1 OVERVIEW
11.2 DENV-3
11.3 DENV-2
11.4 DENV-1
11.5 DENV-4
11.6 OTHERS
12 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION
12.1 OVERVIEW
12.2 MOSQUITO-TO-HUMAN TRANSMISSION
12.3 MOTHER-TO-CHILD- TRANSMISSION
12.4 OTHERS
13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE
13.1 OVERVIEW
13.2 MEDICATION
13.2.1 ACETAMINOPHEN
13.2.2 ANTIBIOTICS
13.2.2.1 Ciprofloxacin
13.2.2.2 Chloramphenicol
13.2.2.3 Ceftriaxone
13.2.2.4 Ofloxacin
13.2.2.5 Others
13.2.3 IMMUNOGLOBULINS
13.2.4 CORTICOSTEROIDS
13.2.5 ANTI-VIRALS
13.2.6 OTHERS
13.3 SUPPORTIVE CARE
13.4 VACCINATION
13.4.1 DENGVAXIA (CYD-TDV)
13.4.2 DENVAX (TAK-003)
13.4.3 TETRAVAX-DV
13.4.4 TDEN PIV
13.5 OTHERS
14 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY
14.1 OVERVIEW
14.2 UNCOMPLICATED
14.3 SEVERE
15 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULES
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
16 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
16.1 OVERVIEW
16.2 PRESCRIPTION
16.3 OVER THE COUNTER (OTC)
17 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOME HEALTHCARE
17.3 HOSPITALS
17.4 SPECIALTY CLINICS
17.5 OTHERS
18 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 RETAIL PHARMACIES
18.3 HOSPITAL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 NORTH AMERICA DENGUE TREATMENT MARKET, BY GEOGRAPHY
19.1 NORTH AMERICA
19.1.1 MEXICO
19.1.2 U.S.
19.1.3 CANADA
20 NORTH AMERICA DENGUE TREATMENT MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 VIATRIS INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 COMPANY SHARE ANALYSIS
22.1.3 PRODUCT PORTFOLIO
22.1.4 RECENT DEVELOPMENT
22.2 PFIZER INC.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENT
22.4 PERRIGO COMPANY PLC
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 GLAXOSMITHKLINE PLC
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 COMPANY SHARE ANALYSIS
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENT
22.6 DR. REDDY’S LABORATORIES LTD.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENT
22.7 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENTS
22.9 ABIVAX
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 AUROBINDO PHARMA
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 BAXTER
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENT
22.12 EMERGEX VACCINES
22.12.1 COMPANY SNAPSHOT
22.12.2 PRODUCT PORTFOLIO
22.12.3 RECENT DEVELOPMENTS
22.13 HIKMA PHARMACEUTICALS PLC
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENT
22.14 SANOFI
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
Liste des tableaux
LIST OF TABLES
TABLE 1 NORTH AMERICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 16 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 21 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 22 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 27 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 29 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 32 NORTH AMERICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 33 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 35 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 36 NORTH AMERICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 37 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 38 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 41 NORTH AMERICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 42 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 43 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 59 MEXICO DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 60 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 MEXICO MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 MEXICO ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 MEXICO OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 MEXICO VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 70 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 73 U.S. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 74 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 U.S. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.S. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 U.S. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 80 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 U.S. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 83 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 84 U.S. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 86 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 87 CANADA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 88 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 CANADA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 CANADA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 CANADA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 CANADA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 94 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 CANADA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 98 CANADA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Liste des figures
LIST OF TABLES
TABLE 1 NORTH AMERICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 16 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 21 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 22 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 27 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 29 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 32 NORTH AMERICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 33 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 35 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 36 NORTH AMERICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 37 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 38 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 41 NORTH AMERICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 42 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 43 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 59 MEXICO DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 60 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 MEXICO MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 MEXICO ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 MEXICO OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 MEXICO VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 70 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 73 U.S. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 74 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 U.S. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.S. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 U.S. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 80 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 U.S. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 83 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 84 U.S. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 86 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 87 CANADA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 88 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 CANADA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 CANADA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 CANADA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 CANADA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 94 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 CANADA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 98 CANADA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DENGUE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DENGUE TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DENGUE TREATMENT MARKET: MARKET END USER GRID
FIGURE 10 NORTH AMERICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE NORTH AMERICA DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DENGUE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA DENGUE TREATMENT MARKET
FIGURE 15 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020
FIGURE 16 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020
FIGURE 20 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 23 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020
FIGURE 24 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 26 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 28 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).
FIGURE 30 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 31 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 34 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020
FIGURE 36 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)
FIGURE 38 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020
FIGURE 40 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA DENGUE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 52 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DENGUE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DENGUE TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DENGUE TREATMENT MARKET: MARKET END USER GRID
FIGURE 10 NORTH AMERICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE NORTH AMERICA DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DENGUE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA DENGUE TREATMENT MARKET
FIGURE 15 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020
FIGURE 16 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020
FIGURE 20 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 23 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020
FIGURE 24 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 26 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 28 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).
FIGURE 30 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 31 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 34 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020
FIGURE 36 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)
FIGURE 38 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020
FIGURE 40 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA DENGUE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 52 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
